Diarrhea News and Research

Latest Diarrhea News and Research

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

Researchers identify starting points for preventing diarrheal disease outbreaks in remote Africa

Using a simple survey tool, a team of researchers has done what complex studies have failed to do -- provide data that identifies starting points for preventing diarrheal disease outbreaks in at least one region of Africa.

18 Sep 2013

Understanding essential role of gut microbes in immune system

A new understanding of the essential role of gut microbes in the immune system may hold the key to dealing with some of the more significant health problems facing people in the world today, Oregon State University researchers say in a new analysis.

17 Sep 2013

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.

17 Sep 2013

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Amgen today announced the publication of a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer.

12 Sep 2013

Study finds low doses of vancomycin to be effective in treating serious C-difficile infection

Clostridium difficile infection (CDI) treatment in a hospital setting using low dose oral vancomycin showed similar effectiveness compared to high dose, according to a new study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University.

12 Sep 2013

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.

11 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

Annual treated wastewater in North America roughly equals volume of Niagara Falls; less than 4% is reused

Amid growing competition for freshwater from industry and cities, coupled with a rising world shortage of potash, nitrogen and phosphorus, an international study predicts a rapid increase in the use of treated wastewater for farming and other purposes worldwide.

7 Sep 2013

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

UCLA researchers explain Post-Diverticulitis Irritable Bowel Syndrome

UCLA researchers have described a new form of irritable bowel syndrome that occurs after an acute bout of diverticulitis, a finding that may help lead to better management of symptoms and relief for patients.

6 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules.

4 Sep 2013

European Commission approves Stivarga tablets for treatment of patients with mCRC

Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the European Commission has approved Stivarga® (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC).

30 Aug 2013

Texas A&M University biologist receives federal grant to study Clostridium difficile

A Texas A&M University biologist has received a federal grant to study the fecal samples of hundreds of people to better understand the gut bacteria Clostridium difficile - the cause of some 14,000 deaths a year in America - and to help lay the basic science foundation to develop drugs to combat its deadly results.

30 Aug 2013

Experts share tips on preventing ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention.

29 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Diarrhea News and Research

Latest Diarrhea News and Research

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

Researchers identify starting points for preventing diarrheal disease outbreaks in remote Africa

Understanding essential role of gut microbes in immune system

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Study finds low doses of vancomycin to be effective in treating serious C-difficile infection

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Annual treated wastewater in North America roughly equals volume of Niagara Falls; less than 4% is reused

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

UCLA researchers explain Post-Diverticulitis Irritable Bowel Syndrome

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

European Commission approves Stivarga tablets for treatment of patients with mCRC

Texas A&M University biologist receives federal grant to study Clostridium difficile

Experts share tips on preventing ovarian cancer

FDA grants Priority Review designation to sNDA for Nexavar tablets

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in